firstwordpharmaMarch 15, 2019
Tag: Roche , mabthera , pemphigus vulgaris
Roche announced Friday that regulators in Europe approved MabThera (rituximab) for the treatment of adults with moderate-to-severe pemphigus vulgaris (PV). The company noted that the drug "is the first biologic therapy approved by the European Commission for PV and the first major advancement in the treatment of the disease in more than 60 years."
The FDA approved MabThera in June last year for the treatment of patients with PV.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: